4.5 Article

Cellular and Pharmacological Selectivity of the Peroxisome Proliferator-Activated Receptor-beta/delta Antagonist GSK3787

Journal

MOLECULAR PHARMACOLOGY
Volume 78, Issue 3, Pages 419-430

Publisher

AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
DOI: 10.1124/mol.110.065508

Keywords

-

Funding

  1. National Institutes of Health National Cancer Institute [CA124533, CA126826, CA141029]
  2. Deutsche Forschungsgemeinschaft [SFB-TR17/A3]
  3. NATIONAL CANCER INSTITUTE [ZIABC005708, R01CA126826, R01CA141029, R01CA124533] Funding Source: NIH RePORTER

Ask authors/readers for more resources

The availability of high-affinity agonists for peroxisome proliferator-activated receptor-beta/delta (PPAR beta/delta) has led to significant advances in our understanding of the functional role of PPAR beta/delta. In this study, a new PPAR beta/delta antagonist, 4-chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), was characterized using in vivo and in vitro models. Orally administered GSK3787 caused antagonism of 4-[2-(3-fluoro-4-trifluoromethyl-phenyl)-4-methyl-thiazol-5-ylmethylsulfanyl]-2-methylphenoxy}-acetic acid (GW0742)-induced up-regulation of Angptl4 and Adrp mRNA expression in wild-type mouse colon but not in Ppar beta/delta-null mouse colon. Chromatin immunoprecipitation (ChIP) analysis indicates that this correlated with reduced promoter occupancy of PPAR beta/delta on the Angptl4 and Adrp genes. Reporter assays demonstrated antagonism of PPAR beta/delta activity and weak antagonism and agonism of PPAR gamma activity but no effect on PPAR alpha activity. Time-resolved fluorescence resonance energy transfer assays confirmed the ability of GSK3787 to modulate the association of both PPAR beta/delta and PPAR gamma coregulator peptides in response to ligand activation, consistent with reporter assays. In vivo and in vitro analysis indicates that the efficacy of GSK3787 to modulate PPAR gamma activity is markedly lower than the efficacy of GSK3787 to act as a PPAR beta/delta antagonist. GSK3787 antagonized GW0742-induced expression of Angptl4 in mouse fibroblasts, mouse keratinocytes, and human cancer cell lines. Cell proliferation was unchanged in response to either GW0742 or GSK3787 in human cancer cell lines. Results from these studies demonstrate that GSK3787 can antagonize PPAR beta/delta in vivo, thus providing a new strategy to delineate the functional role of a receptor with great potential as a therapeutic target for the treatment and prevention of disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available